Development and in vitro evaluation of microparticles of fluoxetine in galactomannan against biofilms of S. aureus methicilin resistant

Josino, Maria Aparecida Alexandre; Silva, Cecília Rocha da; Neto, João Batista de Andrade; Barroso, Fátima Daiana Dias; Silva, Lisandra Juvêncio da; Cavalcanti, Bruno C.; Moraes, Manoel Odoríco de; Brito, Débora Hellen Almeida de; Ricardo, Nágila Maria Pontes Silva; Júnior, Hélio Vitoriano Nobre

doi:10.1016/j.carbpol.2020.117184

Cited by 5 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Use of Micro/Nanoparticles for Antibiotics 3.2.1. Microparticles A safe and efficient antibiotic administration system is essential to delivering therapeutic agents successfully [45,46]. Therefore, microparticles have emerged as low-cost alternatives with ease of synthesis, greater stability, and high drug transport capacity, leading them to be widely used as locally controlled drug delivery systems [46].…”

Section: Use Of Genomics and Resistant Genes For Antibioticsmentioning

confidence: 99%

“…Microparticles A safe and efficient antibiotic administration system is essential to delivering therapeutic agents successfully [45,46]. Therefore, microparticles have emerged as low-cost alternatives with ease of synthesis, greater stability, and high drug transport capacity, leading them to be widely used as locally controlled drug delivery systems [46]. Some examples of microparticles containing antibiotics are from Rezić et al [47], who developed silver (Ag) and zinc (Zn) particles, metals with potential antimicrobial activity, in different sizes (120 and 450 µm) and formulations with or without chitosan.…”

Section: Use Of Genomics and Resistant Genes For Antibioticsmentioning

confidence: 99%

See 1 more Smart Citation

Innovative Biomedical and Technological Strategies for the Control of Bacterial Growth and Infections

Matias,

Damasceno,

Pereira

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Antibiotics comprise one of the most successful groups of pharmaceutical products. Still, they have been associated with developing bacterial resistance, which has become one of the most severe problems threatening human health today. This context has prompted the development of new antibiotics or co-treatments using innovative tools to reverse the resistance context, combat infections, and offer promising antibacterial therapy. For the development of new alternatives, strategies, and/or antibiotics for controlling bacterial growth, it is necessary to know the target bacteria, their classification, morphological characteristics, the antibiotics currently used for therapies, and their respective mechanisms of action. In this regard, genomics, through the sequencing of bacterial genomes, has generated information on diverse genetic resources, aiding in the discovery of new molecules or antibiotic compounds. Nanotechnology has been applied to propose new antimicrobials, revitalize existing drug options, and use strategic encapsulating agents with their biochemical characteristics, making them more effective against various bacteria. Advanced knowledge in bacterial sequencing contributes to the construction of databases, resulting in advances in bioinformatics and the development of new antimicrobials. Moreover, it enables in silico antimicrobial susceptibility testing without the need to cultivate the pathogen, reducing costs and time. This review presents new antibiotics and biomedical and technological innovations studied in recent years to develop or improve natural or synthetic antimicrobial agents to reduce bacterial growth, promote well-being, and benefit users.

show abstract

Section: Use Of Genomics and Resistant Genes For Antibioticsmentioning

confidence: 99%

Section: Use Of Genomics and Resistant Genes For Antibioticsmentioning

confidence: 99%

Innovative Biomedical and Technological Strategies for the Control of Bacterial Growth and Infections

Matias,

Damasceno,

Pereira

et al. 2024

Biomedicines

View full text Add to dashboard Cite

show abstract

“…The inlet and outlet temperatures were 120 and 90 °C, respectively. The feed flow was 10 mL/min and the aspirator flow was 35m 3 /h 8 as described in 23 .…”

Section: Encapsulation Of Fluoxetinmentioning

confidence: 99%

“…After the end of treatment (24 hours) with FLX and FLX-Galact at concentrations of 100 and 250 µg/mL, determined from tests carried out previously with microparticles of galactomannan/ fluoxetine against methicillin-resistant S. aureus 23 , cells were washed with ice-cold PBS and re-cultivated in a complete RPMI medium for 48 h. Colchicine (0.0016%) was added 2 hours before fixation (72 h). Chromosomes were prepared according to standard procedures 10.…”

Section: Chromosomal Aberrations (Cas) Testmentioning

confidence: 99%

Mutagenic Evaluation of Fluoxetine and Fluoxetine-Galactomannan Complex Through the Analysis of Chromosomal Aberrations in Human Peripheral Leukocytes and Salmonella typhimurium/Microssome Assay

et al. 2022

View full text Add to dashboard Cite

Objetivos: avaliar o potencial mutagênico da fluoxetina e da fluoxetina-galactomanana. Métodos: Teste de aberração cromossômica e ensaio de mutagenicidade de Salmonella typhimurium /microssoma. Resultados: a fluoxetina (250 µg/mL) pode causar quebras cromossômicas de leucócitos tratados e aumentar a frequência de reversão das cepas testadoras de S. typhimurium /microssoma apenas na concentração mais alta (5 mg/mL), enquanto a fluoxetina encapsulada em galactomanano não causou essas alterações (leucócitos e cepas de S. typhimurium). Conclusão: a fluoxetina mostrou um efeito mutagênico detectável apenas em altas concentrações em modelos eucarióticos e procarióticos. Além disso, o complexo fluoxetina/galactomanan, neste primeiro momento, evitou a mutagenicidade atribuída à fluoxetina, ressaltando que o presente processo de encapsulamento pode ser uma alternativa na prevenção desses efeitos in vitro.

show abstract

Biological macromolecules in drug delivery

Nayak¹,

Hasnain²,

Behera

et al. 2022

Biological Macromolecules

View full text Add to dashboard Cite

Development and in vitro evaluation of microparticles of fluoxetine in galactomannan against biofilms of S. aureus methicilin resistant

Cited by 5 publications

References 28 publications

Innovative Biomedical and Technological Strategies for the Control of Bacterial Growth and Infections

Innovative Biomedical and Technological Strategies for the Control of Bacterial Growth and Infections

Mutagenic Evaluation of Fluoxetine and Fluoxetine-Galactomannan Complex Through the Analysis of Chromosomal Aberrations in Human Peripheral Leukocytes and Salmonella typhimurium/Microssome Assay

Biological macromolecules in drug delivery

Contact Info

Product

Resources

About